
EVAX Stock Forecast & Price Target
EVAX Analyst Ratings
Bulls say
Evaxion is a clinical-stage TechBio company with a proprietary AI platform that decodes the human immune system to develop novel vaccines for cancer and infectious diseases. The company presented promising results for a personalized GBM vaccine at the 2026 AACR meeting and is now pivoting to autoimmune disease therapies, with plans to select 2-3 lead indications by 1H26. This shift in focus could increase the company's licensing opportunities and potential market reach, making Evaxion a strong investment option.
Bears say
Evaxion is a clinical-stage TechBio company with a negative outlook due to its high risk of dilution and competition in the market. While the company's AI platform shows potential, it has not yet proven its efficacy in clinical trials. With a projected net present value of only $129M, the company's current valuation is overinflated and does not justify a 12-month price target of $16 per ADS.
This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.
EVAX Analyst Forecast & Price Prediction
Start investing in EVAX
Order type
Buy in
Order amount
Est. shares
0 shares